Teleflex Incorporated
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stuart A. Randle
- Full Time Employees
- 14,100
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 550 East Swedesford Road Wayne PA United States of America 19087-1603
- IPO Date
- Mar 17, 1980
- CIK
- 0000096943
- Website
- teleflex.com
- Similar Companies
- Business
- Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical technologies focused on improving patient outcomes through innovative devices in critical care, surgery, and interventional procedures. Founded in 1943 and headquartered in Wayne, Pennsylvania, the company designs, develops, manufactures, and markets a diverse portfolio of single-use and reusable medical devices serving hospitals, healthcare providers, and clinicians worldwide across more than 150 countries, with manufacturing facilities, distribution centers, and operations spanning North America, Europe, Asia-Pacific, Latin America, and other regions. Its core segments include Vascular and Interventional, which encompasses central venous catheters, peripherally inserted central catheters (PICCs), dialysis catheters, coronary catheters, structural heart support devices, peripheral intervention products, mechanical circulatory support platforms, and sheath introducers; Surgical, featuring laparoscopic instruments, surgical clips, sutures, single-use and reusable devices for various procedures including the Titan Stapler and automated polymer clip appliers; Anesthesia, offering laryngeal masks, endotracheal tubes, and airway management solutions such as LMA and refreshed laryngoscope families; Interventional Urology, highlighted by the UroLift System for benign prostatic hyperplasia (BPH), Barrigel rectal spacing system for prostate cancer treatments, and devices for urinary conditions; OEM, providing custom diagnostic and interventional catheters, balloon catheters, bioabsorbable sutures, yarns, resins, and extrusions for other medical device manufacturers; Cardiac Care, including angiography catheters and guidewires; Emergency Medicine, with hemostatic devices like QuikClot Control+ for internal and external bleeding, EZ-IO intraosseous access systems, and OnControl bone access devices; and Respiratory and Urology products under Other categories. Teleflex operates through trusted brands such as Arrow, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift, Weck, and MANTA, targeting high-acuity environments like intensive care units, emergency departments, catheter labs, and operating rooms. In recent developments, Teleflex completed its $895 million acquisition of substantially all of Biotronik's Vascular Intervention business in July 2025, enhancing its global cath lab presence with advanced coronary and peripheral intervention portfolios, including potential resorbable scaffold technologies, and integrating robust R&D and manufacturing capabilities. The company secured a key contract with Vizient, Inc., effective January 2025, to supply central venous and arterial access catheters to over 65% of U.S. acute care providers, bolstering its market penetration. Teleflex expanded internationally by launching the Barrigel system in Japan in August 2025 and advancing its central venous catheter portfolio in EMEA; it anticipates FDA clearances and launches in late 2025 for products like the Ringer Catheter with blood-flow balloon technology, updated EZ-IO systems, and new ligation tools following Palette Life Sciences integration. In February 2025, Teleflex announced plans to separate its Urology, Acute Care, and OEM businesses into a new independent publicly traded company via a tax-free spin-off targeted for mid-2026, allowing RemainCo to concentrate on high-growth hospital-focused segments with projected 6%+ revenue growth, streamlined operations from 19 to seven manufacturing sites, and double-digit EPS expansion, while optimizing capital allocation for R&D, acquisitions, debt reduction, dividends, and share repurchases. These strategic moves, alongside 2024 revenue of approximately $3.05 billion and 14,100 employees, position Teleflex for accelerated innovation and shareholder value in competitive medical device markets.
Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)
Teleflex Incorporated Announces Pricing of $500 Million Senior Notes Offering
TFX Stock Setup: Valuation, Leverage, and a Neutral Zacks Rank
Teleflex Incorporated Announces Private Offering of $500 Million of Senior Notes Due 2032
Teleflex Divestitures: What Investors Should Watch in 2026
Teleflex Showcases New Clinical Data at Leading Urological Congresses Highlighting Patient Experience Advantages of the UroLift™ System and Long-Term Toxicity Reduction with Barrigel™ Rectal Spacer
Teleflex Announces Quarterly Dividend
TFX Stock Down Post Q1 Earnings & Revenue Beat, Margins Crash
Teleflex Incorporated (TFX) Q1 2026 Earnings Call Transcript
Compared to Estimates, Teleflex (TFX) Q1 Earnings: A Look at Key Metrics
Teleflex (TFX) Tops Q1 Earnings and Revenue Estimates
Teleflex Reports First Quarter Financial Results and Full Year 2026 Outlook
Teleflex (TFX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Teleflex Appoints Jason Weidman as President and CEO
Teleflex Announces First Quarter 2026 Earnings Conference Call Information
A Look at Teleflex Inc (TFX) After 5.5% Decline -- GF Value $183.22 vs Price $124.75
CVC, GTCR weigh taking Teleflex private, Bloomberg News reports
Teleflex Incorporated Investigated by the Portnoy Law Firm
Teleflex Announces Governance Updates
Irenic Comments on Teleflex's Announcement That It Is Open to Strategic Alternatives